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Abdominal aortic aneurysm (AAA) disease is characterized by an asymptomatic, permanent,
focal dilatation of the abdominal aorta progressing towards rupture, which confers significant
mortality. Patient management and surgical decisions rely on aortic diameter measurements
via abdominal ultrasound surveillance. However, AAA rupture can occur at small diameters or
may never occur at large diameters, implying that anatomical size is not necessarily a sufficient
indicator. Molecular imaging may help identify high-risk patients through AAA evaluation
independent of aneurysm size, and there is the question of the potential role of positron
emission tomography (PET) and emerging role of novel radiotracers for AAA. Therefore, this
review summarizes PET studies conducted in the last 10 years and discusses the usefulness of
PET radiotracers for AAA risk stratification. The most frequently reported radiotracer was
[18F]fluorodeoxyglucose, indicating inflammatory activity and reflecting the biomechanical
properties of AAA. Emerging radiotracers include [18F]-labeled sodium fluoride, a calcification
marker, [64Cu]DOTA-ECL1i, an indicator of chemokine receptor type 2 expression, and
[18F]fluorothymidine, a marker of cell proliferation. For novel radiotracers, preliminary trials
in patients are warranted before their widespread clinical implementation. AAA rupture risk is
challenging to evaluate; therefore, clinicians may benefit from PET-based risk assessment to
guide patient management and surgical decisions.
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Abbreviations
AAA Abdominal aortic aneurysm
CT Computed tomography
EVAR Endovascular aortic repair
[18F]FDG [18F]fluorodeoxyglucose
[18F]FLT [18F]fluorothymidine
[18F]NaF [18F]-labeled sodium fluoride
MRI Magnetic resonance imaging
PET Positron emission tomography
SoFIA3 Sodium fluoride imaging of AAA
USS Ultrasound scanning
BACKGROUND
Abdominal aortic aneurysm (AAA) disease is char-
acterized by localized, irreversible dilatation of the
abdominal aorta from a normal diameter of approxi-
mately 10–20 mm to an aneurysmal diameter of 30 mm
or greater. AAA is asymptomatic, yet simultaneously
progressive towards rupture and profound internal
bleeding, resulting in a high mortality rate in the range
of 59–83% for patients with ruptured AAA who cannot
access a hospital promptly and do not undergo
surgery.1–3 From 2005 to 2012, 39,740 aneurysm-asso-
ciated deaths occurred in England alone.4 Various
environmental and genetic risk factors contribute to
the development and progression of AAA; the predom-
inant risk factors of AAA include advanced age, male
sex, smoking, and elevated blood pressure.1,5,6 Emerg-
ing evidence also suggests that diabetes may play a
protective role in patients who are susceptible to
developing AAA; however, this correlation requires
further investigation.7,8
SCOPE OF THE CLINICAL PROBLEM
Early-stage AAA does not manifest with any
apparent signs or symptoms; therefore, it is usually
diagnosed incidentally during unrelated medical check-
ups or through screening programs, which have been
formally launched in several countries including the UK,
the US, and Sweden.9–12 The National Health Service
AAA Screening Programme was fully implemented in
2013 in England to offer routine ultrasound scanning
(USS)-based screening for all men 65 years of age and
older. This program was established based on the results
of the UK Multicentre Aneurysm Screening Study,
which demonstrated a nearly 50% reduction in AAA-
related mortality risk after 13 years in men invited for
screening compared with that in men who did not
undergo screening (0.66% vs 1.12%). This reduction
was also found to be associated with an incremental
cost-effectiveness ratio of £7,600 per quality-adjusted
life years gained at 10 years.13,14 With a maximum
reported sensitivity of 95% and specificity of nearly
100%, USS is predominantly used in the clinic to screen
for AAA because of its ease of operability, low costs,
low post-imaging workload and instantaneous results,
and widespread availability.3 It is important to note here
that although there is extensive ongoing research to
establish more reliable and informative risk markers of
AAA, the only indicator that is used consistently in the
clinic is aortic size, which is derived from serial USS, or
occasionally, computed tomography (CT). This is the
simplest and most convenient parameter to extract using
USS, but may not always accurately reflect prognosis, as
small AAA has been reported to rupture, while large
AAA has been reported as remaining intact.15 Therefore,
the inability to accurately predict the prognosis of
patients with AAA and stratify patients according to
AAA risk remains a significant unmet clinical challenge.
In this context, molecular imaging may have a
significant role in assessing AAA evolution. Positron
emission tomography (PET) imaging offers a means to
quantitatively measure molecular mechanisms related to
AAA even at early stages as an adjunctive tool to USS-
based screening and surveillance. PET is an attractive
functional modality to reveal the underlying molecular
changes that occur before the more apparent anatomical
changes associated with AAA progression. The use of
PET with a suitable radiotracer may then successfully
help personalize a surveillance regimen or define a more
precise intervention threshold to prevent aortic compli-
cations. Furthermore, it may contribute to the discovery
of an appropriate pharmacological treatment for AAA,
as currently, the only viable treatment option available is
surgical intervention, the indication for which is based
solely on the aortic size, as measured using USS.
Establishing a pharmacological treatment that could
reduce or even reverse AAA progression is a strategic
aim of AAA-related research, but this necessitates a
stratification imaging biomarker that could (a) help
select patients who would benefit from such treatment,
(b) predict AAA growth and rupture and refine watchful
waiting regimens, (c) determine patient-specific inter-
vention thresholds, or (d) be applied in all the
aforementioned applications. Therefore, this review
summarizes preclinical and clinical PET studies pub-
lished in the last 10 years and discusses the usefulness of
PET for AAA risk stratification.
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PRECLINICAL STUDIES
Much of our pathological understanding of AAA in
patients is based on aortic tissue acquired during surgery
(i.e., late-stage disease); hence, theories derived from
these samples may not accurately represent the mech-
anisms of early-stage disease, when a novel
pharmacological therapy may be administered. Preclin-
ical studies of AAA are the first step in achieving a more
complete picture of early-stage AAA pathophysiology,
which may help establish stratification biomarkers that
may be translated to the clinic. Table 1 presents the
details of all preclinical PET studies of AAA published
between 2010 and 2020.
Preclinical studies are conducted with the aim of
better matching animal models to the equivalent stage of
human AAA. Calcification, proliferation, angiogenesis,
and inflammation are some key processes that contribute
to the AAA pathogenesis16; elucidating how these
mechanisms are inter-connected at various stages of
AAA progression can guide the development of more
longitudinally representative preclinical models. For
example, English et al. demonstrated that the uptake of
[64Cu]DOTA-ECL1i shows little variation between days
7 and 14 post-aneurysm induction in the porcine
pancreatic elastase-induced AAA murine model, reflect-
ing non-fluctuating levels of vascular wall inflammation
during this period.17 Another [64Cu]-based radiotracer,
[64Cu]NOTA-TRC105-Fab, has been shown to exhibit
high uptake in the calcium-induced murine model,
indicating increased angiogenic activity; however, its
high residual blood pool activity even 24 hours post-
injection remains a key limitation.18 Using the angio-
tensin II-induced AAA murine model, Gandhi et al.
showed that there is increased [18F]fluorothymidine
([18F]FLT) uptake on day 14 post-aneurysm induction,
but this uptake is significantly reduced on day 28.19
These findings have important implications in support-
ing the idea of early-stage cellular remodeling that may
drive disease progression, a notion that has been
introduced and deliberated by several groups.20–22 In
the future, knowledge gained from these studies may
facilitate early-stage risk stratification; however, further
preclinical and clinical investigations are warranted to
reinforce this theory.23 Li et al. demonstrated that the
uptake of [18F]-labeled sodium fluoride ([18F]NaF),
reflecting microcalcification, is increased between days
14 and 28 in the angiotensin II-induced AAA murine
model preceding notable aortic expansion.24 In the same
model, Nahrendorf et al. showed that the uptake of
[18F]-cross-linked iron oxide ([18F]CLIO) in AAA is
associated with the risk of AAA growth and rupture.25
However, a key drawback to the use of nanoparticle-
based radiotracers such as [18F]CLIO is their extended
circulation period, necessitating delayed imaging to
avoid capturing the blood pool activity that may mask
AAA uptake. Radiotracers consisting of smaller
nanoparticles with a shorter clearance time may evade
this issue. These are just a few examples of studies that
have attempted to investigate the time course of bio-
logical events in AAA, which can help develop more
informative preclinical models of AAA that are easily
translatable to the clinic.
Nevertheless, the translation of preclinical PET
research to the clinic is not free of hurdles. There is an
overwhelming cost of introducing new radiotracers in
the clinic, along with long-standing regulations that may
prevent or delay the implementation of radiotracers not
readily used for other applications such as cancer
diagnostics. Few centres have easy access to a cyclotron
for radiotracer production, thereby largely limiting
centers to using radiotracers with sufficiently workable
half-lives such as radiotracers labeled predominantly
with [18F]; instead, alternatives that do not require a
cyclotron for production such as [68Ga]-labeled radio-
tracers may be employed.26 Moreover, the translational
success of preclinical findings may then be influenced by
several factors, such as differences in toxicology and
pharmacokinetics27; gaining a better understanding of
these factors will ultimately benefit the clinical transla-
tion of important preclinically validated biomarkers.
CLINICAL STUDIES
Over the last several decades, the incidence of AAA
rupture has decreased. This is largely attributed to the
implementation of AAA screening programs and novel
therapeutic interventions, such as endovascular aortic
repair (EVAR). That being said, the low rupture rate of
small aneurysms and risks associated with surgery do
not sufficiently rationalize the routine repair of small
AAA.28 Clinical guidelines on the use of EVAR have
been amended often, owing to its reduced long-term
durability and moderate long-term survival benefits.29
Therefore, by non-invasively detecting established bio-
logical targets, such as inflammation with
[18F]fluorodeoxyglucose ([18F]FDG) PET, clinicians
may be able to identify patients with a high risk of
clinical events and those who may benefit the most from
elective repair. Generally, PET radiotracers approved for
non-AAA applications have facilitated clinical studies of
AAA. Table 2 presents the details of all clinical PET
studies of AAA conducted between 2010 and 2020,
revealing as expected that the predominant radiotracer in
use is [18F]FDG.
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CONTROVERSY OF [18F]FDG
[18F]FDG is the most common radiotracer utilized
for PET imaging. As presented in Table 1 and Table 2,
there has been an extensive focus on markers of
inflammatory activity, evidenced by the overwhelming
predominance of [18F]FDG PET studies: 5 of 11
preclinical and 24 of 28 clinical studies. With its
widespread availability and well-established safety pro-
file, [18F]FDG is a typically universal starting point for
clinical PET research. The intracellular distribution of
[18F]FDG is associated with the degree of metabolic
activity and inflammation in regions of uptake.30
Table 1. Preclinical PET studies of AAA conducted between 2010 and 2020.
Refs. Species Radiotracer Targeted biomarker Key conclusions
65 Rats [18F]FDG,
[11C]PBR28
Aortic wall inflammation AAA wall inflammation can be detected
using [18F]FDG and [11C]PBR28
39 Rats [18F]FDG Rupture prediction Increased pre-rupture glucose uptake may
be associated with increased inflammation





There is no change in [64Cu]DOTA-ECL1i
uptake from day 7 to day 14 in PPE AAA,
regardless of aortic diameter, and there is
approx. 29 more uptake in AAA that
proceeds to rupture
19 Mice [18F]FLT Cell proliferation [18F]FLT uptake is increased during the active
growth phase of AngII AAA compared to
that in saline control mice and late-stage
AAA
52 Mice [18F]FPPRGD2 avb3 expression [
18F]FPPRGD2 uptake in AAA may correlate
with vascular inflammation and
neoangiogenesis but not with AAA
diameter
25 Mice [18F]CLIO Macrophages [18F]CLIO may be used to quantify
macrophage content in AAA
66 Rats [18F]FDG Intraluminal thrombus
occurrence
Increased [18F]FDG uptake and growth may
be associated with intraluminal thrombus
occurrence in AAA
41 Rabbits [18F]FDG AAA progression Inflammation plays a key role early in AAA
development
24 Mice [18F]NaF Vascular microcalcification [18F]NaF uptake is increased in AngII AAA
preceding significant aortic expansion on
days 14 to 28, and hydroxyapatite







[18F]FDG may have higher sensitivity than
that of [18F]FCH and [18F]DPA714 in




Angiogenesis [64Cu]NOTA-TRC105-Fab uptake indicates
regions of increased angiogenesis in AAA,
based on cluster of differentiation 105
expression
AAA, abdominal aortic aneurysm; AngII, angiotensin II; [64Cu]DOTA-ECL1i, [64Cu]-(1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid)-extracellular loop 1 inverso; [18F]FCH, [18F]fluoromethylcholine; [18F]CLIO, [18F]-cross-linked iron oxide;
[18F]FDG, [18F]fluorodeoxyglucose; [18F]FLT, [18F]fluorothymidine; [18F]NaF, [18F]-sodium fluoride; PET, positron emission
tomography
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Table 2. Clinical PET studies of AAA conducted between 2010 and 2020.
Refs. Radiotracer Targeted biomarker Key conclusions
44 [18F]FDG Glucose metabolism Metabolic activity levels may not correlate with
aortic size or differ between aneurysms vs
controls
42 [18F]FDG Correlation between inflammation
and histological analysis
[18F]FDG uptake in the aneurysmal wall may be
associated with an active inflammatory process
involving proliferating leukocytes and increased
circulating C-reactive protein
68 [18F]FDG Circulating microRNAs Specific microRNAs are significantly correlated
with [18F]FDG uptake in the aneurysmal wall and
may be directly involved in AAA instability
47 [18F]FDG Prediction of complications after
EVAR
Aortic [18F]FDG uptake may be a predictor of
post-EVAR complications
54 [18F]FCH Incidental AAA detection in
patients with prostate cancer
[18F]FCH PET/CT may be an effective approach for
secondary prevention and stratification of AAA
in patients with prostate cancer
50 [18F]NaF AAA growth and clinical outcomes [18F]NaF uptake may help identify advanced AAA
and may be correlated with aneurysm growth
and clinical AAA events that differ from
established risk factors
40 [18F]FDG Structural stress Increased [18F]FDG is associated with high
mechanical stress of thick intraluminal thrombus
in AAA
55 [18F]FDG Inflammation There is greater inflammation (based on [18F]FDG
PET) and calcification (based on the Agatston
score) in patients with AAA than in patients with
atherosclerosis
38 [18F]FDG Future aneurysm expansion AAA with lower metabolic activity may be more
likely to expand
69 [18F]FDG Correlation between CT texture
analysis data and metabolism
CT textural data may reflect AAA metabolism
measured by [18F]FDG PET
46 [18F]FDG Inflammation [18F]FDG PET/MRI may be used to assess
inflammation in asymptomatic AAA, although
the hotspots of [18F]FDG uptake and late
gadolinium enhancement are not always
aligned
70 [18F]FDG Decision to perform intervention [18F]FDG uptake may be related to the clinical
conditions of patients with AAA who require
intervention
71 [18F]FDG Correlation between metabolic
activity and non-linear finite
element analysis
Greater [18F]FDG activity may be associated with
increased mechanical stress in the AAA wall
72 [18F]FDG Correlation between [18F]FDG
uptake and asymptomatic non-
inflammatory AAA
Low [18F]FDG uptake in asymptomatic AAA
reflects the loss of tissue structure and reduced
cell density
73 [18F]FDG Vascular inflammation and
correlation with USPIO MRI
uptake
[18F]FDG uptake may indicate macrophage
glycolytic activity in AAA but shows a modest
correlation with USPIO uptake
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[18F]FDG uptake on PET has been demonstrated to
correlate with macrophage density in plaques, cardio-
vascular risk factors, the Framingham risk score, and
various inflammatory and glycolysis-related biomarkers,
such as glucose transporters 1 and 3 and total lesion
glycolysis.31–33 Yet, a patient receiving anti-inflamma-
tory drugs has been reported to develop AAA that
rapidly expanded and ruptured34; this case suggests that
inflammation may be fallible as a single indicator of
patient prognosis and may need to be supplemented with
other biomarkers. A downside to the advantage of
[18F]FDG highlighting all regions of active glucose
metabolism is that, as a result, it is difficult to differ-
entiate disease-specific activity. Moreover, the uptake of
[18F]FDG can be influenced by conditions of disease
microenvironments, such as hypoxia or increased
myocardial muscle activity, or the efficiency with which
the microcirculation distributes the radiotracer.35–37
Both preclinical and clinical studies of gold-stan-
dard [18F]FDG PET to assess glucose metabolism and
inflammation in AAA have yielded varying results of
both increased and variable [18F]FDG uptake.38–41 Some
studies have shown that [18F]FDG PET may be useful to
predict AAA expansion and/or progression,42,43 while
other studies have contradicted this.38,44 For example,
Tsuruda et al. showed that increased aortic uptake of
[18F]FDG in patients is associated with active aortic wall
inflammation, which may contribute to AAA progres-
sion and rupture, while patients showing [18F]FDG
uptake in AAA revealed no correlation with aortic
expansion 12 months later in a study by Kotze et al.38,45
Moreover, Nchimi et al. and Huang et al. demonstrated
that [18F]FDG uptake correlates positively with wall
stress and strength in AAA, whereas Barwick et al.
found no significant difference in aortic uptake of
Table 2 continued
Refs. Radiotracer Targeted biomarker Key conclusions
64 [18F]FDG AAA progression [18F]FDG PET/CT and PET/MRI do not correlate
with disease symptoms, AAA progression, or
dissection
74 [18F]FDG Relationship between inflammation
and risk factors
Vascular inflammation plays a role at all stages of
AAA, which may involve the local result of
systemic inflammation
75 [18F]FDG Metabolic changes Metabolic changes in AAA may follow a cyclic
pattern, similar to that observed with changes in
maximal aortic diameter
76 [18F]FDG Infection [18F]FDG PET is useful to diagnose infected AAA
43 [18F]FDG Biomechanical properties Increased [18F]FDG uptake is correlated with AAA
location, wall stress, and patient risk factors
77 [18F]FDG Asymptomatic aneurysmal uptake [18F]FDG uptake may be rare in patients with AAA
of diameter approaching the surgical threshold
78 [18F]FDG Correlation between glucose
metabolism and partial volume
correction
Partial volume correction may be necessary to
quantitatively stratify patients for AAA repair
79 [18F]FDG Inflammation [18F]FDG PET cannot be used to detect chronic




Inflammation Inflammation in AAA cannot be detected using
[11C]PK11195 or [11C]-d-deprenyl
53 [18F]fluciclatide avb3 expression avb3 integrin expression in AAAmay be visualized
ex vivo using [18F]fluciclatide
45 [18F]FDG Aortic wall inflammation Active aortic wall inflammation may contribute to
AAA progression and rupture
81 [18F]FDG Wall stress and metabolic activity High AAA wall stress and accelerated metabolism
may be associated
AAA, abdominal aortic aneurysm; CT, computed tomography; EVAR, endovascular aortic repair; [18F]FCH,
[18F]fluoromethylcholine; [18F]FDG, [18F]fluorodeoxyglucose; [18F]NaF, [18F]-sodium fluoride; MRI, magnetic resonance
imaging; PET, positron emission tomography; USPIO, ultrasmall superparamagnetic iron oxide
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[18F]FDG between patients with infra-renal AAA and
patients without AAA.40,43,44
In a study of [18F]FDG PET and contrast-enhanced
magnetic resonance imaging (MRI), Kuzniar et al.
demonstrated that the hotspots of [18F]FDG uptake and
late gadolinium enhancement rarely coincide in AAA,
although both are associated with aneurysm growth,
raising interesting questions about the distribution of
cellular activity in AAA.46 Collectively, these findings
contribute to a complicated story of glucose metabolism
in AAA. This scenario is further confounded by the lack
of consistency in the type of AAA presentation studied,
such as asymptomatic, symptomatic, end-stage, and/or
early-stage AAA. Meanwhile, [18F]FDG PET may have
a promising role in identifying patients who may be at
risk of experiencing endoleaks after undergoing
EVAR.47–49 Validation of these prior studies would
benefit from larger prospective studies investigating
patients with a consistent type of AAA presentation.
Further data corresponding to kinetic modeling and
corrections for blood flow and volume would also be
informative, lending to more comprehensive analysis
and validation. Therefore, supplementing the informa-
tion yielded by [18F]FDG with information from other
radiotracers may facilitate a more detailed understand-
ing of the molecular workings of AAA.
EMERGING RADIOTRACERS
AAA comprises an intricate environment of various
biological pathways; therefore, other PET radiotracers
are also promising in the context of AAA. The sodium
fluoride imaging of AAA (SoFIA3) trial has shown that
uptake of [18F]NaF, which reflects regions of calcifica-
tion, in patients with end-stage asymptomatic AAA
predicts AAA progression and rupture, providing proof-
of-concept data for the feasibility of a non-[18F]FDG
PET radiotracer for AAA stratification. The findings of
the trial suggest that [18F]NaF PET/CT is an effective
tool to identify AAA disease activity in patients, based
on the localization of the radiotracer in regions of
microcalcification, which in turn, is a susceptibility
marker of aneurysm expansion and rupture early after
AAA formation.50
A key point arising from this study is that aneurysm
size is not necessarily a predictor of rupture; AAA
growth may be non-linear and influenced by biome-
chanical processes that may not necessarily exhibit an
obvious detectable pattern. The SoFIA3 trial demon-
strated that [18F]NaF uptake is a positive predictor of
aneurysm growth and clinical outcomes, which are
independent but supplementary to classic clinical
parameters such as aneurysm diameter.50 The findings
of this trial must be considered in light of the
confounding issue of spill-in contamination from the
nearby bone into the aneurysm; thus, background
correction techniques are likely necessary to provide
more robust quantitative assessments of AAA using
[18F]NaF.51 Alternative radiotracers that may prove to
be useful include markers of other characteristics of
AAA development, such as angiogenesis, using integrin-
or endoglin-targeted agents.18,52,53 Markers of cell
proliferation and chemokine receptors such as
[18F]FLT and [64Cu]DOTA-ECL1i are promising, and
preliminary trials in patients are warranted to determine
if these approaches may translate to the clinic.17,19,23
[18F]fluoromethylcholine, which is commonly imple-
mented in prostate cancer staging, may also be beneficial
to incidentally detect AAA in patients with prostate
cancer.54 With these radiotracer applications, PET
remains an attractive modality to advance our under-
standing of AAA pathophysiology, while novel
molecular tracer agents are introduced, and hybrid
multimodality systems are improved. As PET is readily
accessible and already being used in the clinic, contin-
ued research using PET has practical applications that
are feasible for clinical translation.
OUTLOOK OF PET FOR AAA ASSESSMENT
AAA remains a significant cause of mortality due to
aortic rupture. USS reveals anatomical changes in AAA
size and shape; however, there remain gaps in our
knowledge of the molecular changes that precede
physical manifestation of AAA and in our ability to
visualize these pathological mechanisms at the molec-
ular level. Despite the large number of AAA studies
conducted, our knowledge of AAA pathobiology is
incomplete, and there remains a lack of concrete data to
translate preclinical findings to clinical practice. The
contributions of inflammatory activity, biomechanical
disturbances, calcification, angiogenesis, and cell pro-
liferation to aortic growth and aneurysm progression
remain only partially understood; these may be clarified
with the application of PET imaging utilizing specific
biologically targeted radiotracers. A better understand-
ing of these functional changes in early-stage AAA may
help stratify patients based on rupture risk early in the
disease course and guide appropriate treatment selec-
tion. In this context, the multifactorial pathophysiology
of AAA in humans represents a growing area in
cardiovascular research, largely because clinical studies
of AAA are predominantly limited to using late-stage
aortic tissue obtained during surgery, owing to the
asymptomatic presentation of early-stage AAA and lack
of intervention (and easy access to tissue) at this stage.
Although several risk factors and potential contributors
to the disease process have been identified, such as sex,
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age, comorbidities, and smoking, these are not yet
sufficiently predictive when applied to individual
patients as reliable and accurate assessment methods
for these factors are not yet readily available. Thus, as
management decisions are made based solely on aortic
size, many patients are needlessly subjected to the risks
of aortic repair, even in cases wherein an aneurysm
might not have ruptured if left untreated.
As we move forward, a shift away from the size of
an aneurysm as the sole indicator of AAA repair is
perhaps required. The feasibility of alternative markers
of AAA progression that may be more reliable must be
investigated as adjuncts to traditional USS-based size
information, including circulating biomarkers, four-di-
mensional or dynamic contrast-enhanced MRI findings
such as vascular flow patterns, CT-based calcium scores,
and haemodynamic parameters.55–60 Although anatom-
ical imaging is mainly used in both preclinical and
clinical imaging of AAA, molecular imaging is gaining
increasing importance, and several new studies are
anticipated in forthcoming years. Anatomical and
molecular imaging techniques are not necessarily com-
petitive; rather, they can be complementary in their
usefulness for AAA management. Thus, PET offers a
non-invasive means to detect and evaluate components
of potentially contributing pathways in patients to better
understand AAA development beyond morphological
features. Ultimately, the most successful imaging tracer
will reveal key aspects of AAA formation in humans, be
used for patient risk stratification, and help assess
treatment efficacy in novel clinical trials.61 Introducing a
novel imaging tracer to the clinic is a lengthy and costly
process, akin to drug research and development. Ulti-
mately, novel radiotracers that may also be implemented
in multiple diseases are more likely to undergo rapid and
efficient clinical translation. Considering the rupture rate
of small AAA, a large sample of patients would be
required to demonstrate a novel agent’s value in
assessing rupture risk for AAA smaller than 55 mm in
diameter. Meanwhile, the presence of comorbidities
such as heart and vascular diseases greatly affects a
patient’s outcomes of surgical repair.62 Hence, a tran-
sitional step may be to first investigate patients with
AAA larger than 55 mm in diameter, as they conse-
quently carry a risk of complications, to identify who
may benefit from repair in the presence of comorbidities.
PET TECHNOLOGY AND METHODOLOGY
The ability of PET to yield precise, longitudinal
quantitative data makes it a strong contender for clinical
translation in the context of AAA risk stratification.
Improvements in spatial resolution and the application
of partial volume correction and background activity
adjustments may improve the accuracy and precision of
PET analysis methods in the future.63 One setback of
PET is the potential inter-analytical variability depend-
ing on how the aortic region of interest (ROI) is defined.
Standardizing ROI definitions and analytical methods is
imperative to overcoming this challenge, and a signif-
icant advantage of PET is that data can be reviewed and
corrected post-acquisition for temporal and spatial
resolution, something that USS that does not yet offer.
The ability to perform kinetic modeling of PET data,
which would elucidate radiotracer biodistribution in the
blood circulation, further makes PET an attractive and
useful technology for AAA assessment. The small size
of arteries and vessel walls necessitates the coupling of
PET with anatomical modalities to distinguish radio-
tracer uptake in the aorta from that in surrounding
regions. Standalone PET is typically combined with CT
to add a layer of anatomical information while com-
pensating for the limited spatial resolution of PET. With
their widespread availability and low associated costs,
hybrid PET/CT systems continue to advance towards
becoming a valuable prognostic and risk stratification
tool; meanwhile, the combination of MRI and PET has
also emerged, with the superior advantage of combining
molecular imaging with substantial soft tissue contrast
than that achieved using CT. With these new imaging
systems, PET and MRI data are acquired simultaneously
in a single scan, and the images are promptly co-
registered, effectively reducing misalignment errors.
More studies will confirm whether PET and MRI
parameters are correlated or reveal different types of
information.46,64 Nonetheless, technical developments in
PET and hybrid PET systems will continually help our
understanding of the pathophysiological factors con-
tributing to AAA evolution.
CONCLUSIONS
Despite substantial advances in AAA screening and
management over the years, AAA remains clinically
significant. Management of patients with AAA is cur-
rently based on morphological characteristics derived
from USS-based surveillance, including aortic size and
growth rate. USS provides reliable anatomical data in
this regard. However, the classical anatomy-centered
approach to AAA imaging is insufficient to comprehen-
sively assess rupture risk and factors that may result in
complications associated with repair. Emerging radio-
tracers with PET can provide complementary functional
information at the molecular level. [18F]FDG PET
studies have yielded equivocal results, urging the
introduction of more relevant radiotracers. Importantly,
the strength of PET lies in its ability to elucidate the
molecular evolution of AAA, which can inform the need
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for surgical intervention or response to pharmacological
therapy. Despite the low number of preclinical studies,
these are important for pilot evaluations of novel agents
and improved characterization of existing radiotracers
prior to their clinical translation. Finally, for clinical
translation, the standardization of analysis methods and
improvements in hybrid technology are warranted.
Therefore, in patients with AAA, the road ahead for
PET imaging is promising to facilitate assessments of
functional aortic characteristics that may help distin-
guish patients with rupture-prone AAA requiring
surgery from patients with low-risk AAA for whom a
watchful waiting approach may be sufficient.
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